NEXT PRICE INCREASE IN
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Advancing RNA Excellence Through Shared Intelligence and Insights
Together, We Discover, Disseminate, and Drive Innovation in RNA Therapeutics
Registration is NOW OPEN
Secure Up to $1600 in Savings with Our Launch Price!
Speaker Interviews
RNA Therapeutics and Partnerships: Novo Nordisk's Approach to Innovation
Revolutionizing RNA Therapeutics: La Jolla Labs' AI-Powered Platform Transforms Drug Discovery
Session Spotlights
Progressing mRNA-based Therapeutics and Vaccines to Combat Cancer
- This session examines industry pathways for advancing personalized cancer mRNA vaccines, comparing allogenic versus autologous approaches and addressing delivery challenges.
- Experts review progress in mRNA-encoded immunotherapies and provide insights into future developments with projected 2026 milestones.
Applying An Intricate RNA Design Platform for Immunomodulation, Next-Gen mRNA Vaccines and RNA-based Protein Therapeutics
- This session examines an innovative RNA design platform that enables creation of optimized RNA sequences for immunomodulation, enhancing efficacy of next-generation mRNA vaccines and RNA-based protein therapeutics.
Scaling Oligo-based Therapeutics with Innovation at the forefront
- This session explores cutting-edge advancements in oligonucleotide synthesis, manufacturing, and delivery technologies.
- Industry experts discuss strategies for scaling oligo-based therapeutics from research to commercial production, examining innovative approaches to improve efficacy, safety, and accessibility of siRNAs and antisense oligonucleotides.
Join the community
Follow us on LinkedIn for the latest RNA Leaders updates and news.
Top Companies joining us at RNA Leaders USA
With roots dating back to 1758, Novartis has evolved into a healthcare powerhouse operating in 155 countries. Their strategic pivot toward RNA technologies represents a significant expansion of their therapeutic arsenal. Malgorzata Gonciarz, Global Head of xRNA Therapeutics and Christopher O'Donnell, Global Head of Cardiovascular & Metaboli at Novartis will be joining us at RNA Leaders USA to touch on fostering partnerships within RNA Pharma and Industry and regulatory challenges on Oligonucleotide Development.
This British-Swedish multinational, formed through the 1999 merger of Astra AB and Zeneca Group, has become a frontrunner in RNA delivery innovation. Their Advanced Drug Delivery unit tackles one of RNA therapeutics' greatest challenges: targeted cellular delivery. Annette Bak, who leads this division, will present their proprietary delivery technologies that aim to expand RNA medicines beyond liver applications.
Established in Denmark in 1923, Novo Nordisk transformed from an insulin producer to a diversified healthcare leader. Their recent expansion into nucleic acid therapeutics marks a strategic evolution beyond their traditional strengths. At RNA Leaders USA, Shanthi Ganesh, Senior Scientific Director of Global Nucleic Acid Therapies, will highlight their novel RNAi technology that silences PD-L1 in tumor-associated immune cells, showing promise in remodelling tumor microenvironments and overcoming immunotherapy resistance in preclinical models.
